Multi-target phytotherapeutic and nutraceutical interventions have been proposed as complementary strategies in metabolic dysfunction-associated steatotic liver disease (MASLD), yet the interpretation of treatment-associated changes in interleukin-11 (IL-11) remains uncertain. Historically associated with tissue protection and regeneration, IL-11 has sometimes been regarded as a potentially favorable biomarker; however, recent evidence challenges this interpretation. This Perspective critically reappraises the biological role of IL-11 in metabolic liver disease. A narrative critical appraisal was integrated with evidence-informed mapping of a representative twelve-component phytotherapeutic formula onto processes implicated in hepatic IL-11 induction. Current evidence links hepatic IL-11 signaling through the interleukin-11 receptor alpha (IL-11Rα)/gp130 complex to lipotoxic and oxidative stress, hepatocyte injury, hepatic stellate-cell activation, and fibrogenesis, while cross-sectional human data associate circulating IL-11 with fibrosis severity in MASLD. Four competing, not necessarily mutually exclusive, hypotheses are proposed: upstream suppression (H1), adaptive rise (H2), extrahepatic/off-axis effects (H3), and null/analytical variability (H4), generating testable predictions regarding IL-11 trajectories and biomarker relationships. A treatment-associated increase in circulating IL-11 should therefore not be interpreted a priori as a favorable regenerative response without independent evidence of reduced hepatic injury or fibrogenic activity. A staged validation strategy is proposed to prospectively distinguish among these interpretations.
